Literature DB >> 21332692

Cyclosporin combined with methotrexate in two patients with recalcitrant subacute cutaneous lupus erythematosus.

Annette Klein1, Thomas Vogt, Sabrina M Wenzel, Martin Fleck, Michael Landthaler.   

Abstract

The treatment of subacute cutaneous lupus erythematosus is a therapeutic challenge. Frequently, patients are resistant to or intolerant towards single selected immunosuppressants. In combination, lower doses of methotrexate and cyclosporin A might be used to minimize toxicity. This is the first report of a successful combination of these drugs in two patients suffering from subacute cutaneous lupus erythematosus refractory to standard treatment.
© 2010 The Authors. Australasian Journal of Dermatology © 2010 The Australasian College of Dermatologists.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21332692     DOI： 10.1111/j.1440-0960.2010.00689.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN： 0004-8380            Impact factor:   2.875


  4 in total

Review 1.  Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.

Authors:  Joshua Chang; Victoria P Werth
Journal:  Expert Rev Clin Immunol       Date:  2016-06-01       Impact factor: 4.473

2.  Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.

Authors:  R R Winkelmann; Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-01

Review 3.  An update on the management of refractory cutaneous lupus erythematosus.

Authors:  Alice Verdelli; Alberto Corrà; Elena Biancamaria Mariotti; Cristina Aimo; Valentina Ruffo di Calabria; Walter Volpi; Lavinia Quintarelli; Marzia Caproni
Journal:  Front Med (Lausanne)       Date:  2022-09-23

Review 4.  Cutaneous lupus erythematosus: A review of the literature.

Authors:  Stephanie Clare Blake; Benjamin Silas Daniel
Journal:  Int J Womens Dermatol       Date:  2019-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.